Solid Biosciences (NASDAQ:SLDB) Coverage Initiated by Analysts at Guggenheim

Guggenheim assumed coverage on shares of Solid Biosciences (NASDAQ:SLDB) in a research report released on Friday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $26.00 price target on the stock.

A number of other brokerages have also recently issued reports on SLDB. Wedbush restated an “outperform” rating and issued a $14.00 price objective on shares of Solid Biosciences in a research note on Wednesday, March 11th. Chardan Capital reiterated a “buy” rating and set a $15.00 target price on shares of Solid Biosciences in a research report on Friday. Needham & Company LLC reissued a “buy” rating and issued a $19.00 target price on shares of Solid Biosciences in a research note on Friday. Citigroup reissued a “market outperform” rating on shares of Solid Biosciences in a research report on Wednesday, December 17th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Solid Biosciences in a research note on Thursday, January 22nd. Eleven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Solid Biosciences has an average rating of “Moderate Buy” and a consensus price target of $16.00.

Solid Biosciences Trading Down 1.3%

SLDB opened at $7.03 on Friday. The stock’s 50 day simple moving average is $6.43 and its 200-day simple moving average is $5.79. The stock has a market cap of $547.71 million, a PE ratio of -3.48 and a beta of 2.65. Solid Biosciences has a 1 year low of $2.41 and a 1 year high of $8.72.

Solid Biosciences (NASDAQ:SLDB) last issued its earnings results on Thursday, March 19th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.05). Equities analysts forecast that Solid Biosciences will post -2.84 earnings per share for the current fiscal year.

Insider Activity

In other Solid Biosciences news, CEO Alexander Cumbo sold 80,258 shares of the business’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $6.44, for a total value of $516,861.52. Following the transaction, the chief executive officer directly owned 270,931 shares in the company, valued at $1,744,795.64. The trade was a 22.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Gabriel Brooks sold 28,335 shares of the company’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $6.44, for a total transaction of $182,477.40. Following the sale, the insider directly owned 96,708 shares in the company, valued at $622,799.52. This represents a 22.66% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 597,672 shares of company stock worth $3,816,546 over the last ninety days. Corporate insiders own 1.90% of the company’s stock.

Institutional Investors Weigh In On Solid Biosciences

A number of large investors have recently bought and sold shares of SLDB. Invesco Ltd. raised its position in Solid Biosciences by 29.6% in the 4th quarter. Invesco Ltd. now owns 152,126 shares of the company’s stock valued at $858,000 after purchasing an additional 34,758 shares during the last quarter. XTX Topco Ltd acquired a new position in Solid Biosciences in the fourth quarter worth $201,000. Vestal Point Capital LP grew its holdings in shares of Solid Biosciences by 95.5% during the fourth quarter. Vestal Point Capital LP now owns 5,815,000 shares of the company’s stock worth $32,797,000 after purchasing an additional 2,840,000 shares during the last quarter. Armistice Capital LLC increased its stake in shares of Solid Biosciences by 179.1% in the fourth quarter. Armistice Capital LLC now owns 2,612,000 shares of the company’s stock valued at $14,732,000 after buying an additional 1,676,000 shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC raised its holdings in shares of Solid Biosciences by 168.9% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 182,869 shares of the company’s stock valued at $1,031,000 after buying an additional 114,867 shares during the last quarter. 81.46% of the stock is currently owned by institutional investors.

Key Headlines Impacting Solid Biosciences

Here are the key news stories impacting Solid Biosciences this week:

• Positive Sentiment: Guggenheim started coverage with a Buy and a $26 price target (implies ~272% upside from recent levels), giving formal street-level momentum and a large upside case for the stock. Guggenheim starts coverage (Benzinga)
• Positive Sentiment: Needham reaffirmed Buy with a $19 price target, signaling continued analyst conviction in the company’s clinical progress and longer-term value. Needham reaffirms buy (Benzinga)
• Positive Sentiment: Chardan reaffirmed its Buy rating and $15 target, adding to the cluster of upgrade/reaffirmation headlines that can attract investor attention and trading demand. Chardan reaffirms buy (TickerReport)
• Positive Sentiment: Solid reported positive interim Phase 1/2 INSPIRE data for SGT-003 at the 2026 MDA meeting; the readout highlights generally favorable tolerability in 41 dosed participants—this is the primary fundamental catalyst supporting higher valuations. SGT-003 interim data (GlobeNewswire)
• Neutral Sentiment: The company issued its Q4 and full-year 2025 results and broader business updates; the release contains operational context and program timelines that investors will parse for runway and development plans. Q4 & full-year 2025 results (FinanzNachrichten)
• Negative Sentiment: SLDB missed Q4 EPS expectations (reported -$0.53 vs. consensus -$0.48), underlining ongoing losses and near-term profitability risk that likely capped the stock’s upside today. Earnings press release (Quartr)

Solid Biosciences Company Profile

Solid Biosciences Inc is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.

Solid’s lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector.